NGM Biopharmaceuticals Revenue 2018-2021 | NGM

NGM Biopharmaceuticals revenue from 2018 to 2021. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
NGM Biopharmaceuticals Annual Revenue
(Millions of US $)
2020 $87
2019 $104
2018 $109
2017 $77
NGM Biopharmaceuticals Quarterly Revenue
(Millions of US $)
2021-06-30 $17
2021-03-31 $22
2020-12-31 $20
2020-09-30 $23
2020-06-30 $20
2020-03-31 $24
2019-12-31 $31
2019-09-30 $22
2019-06-30 $25
2019-03-31 $26
2018-12-31 $47
2018-09-30 $21
2018-06-30 $22
2018-03-31 $19
2017-12-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.722B $0.087B
NGM Biopharmaceuticals Inc. is focused on developing novel therapeutics for underlying cardio-metabolic, liver, oncologic and ophthalmic diseases. The company's product pipeline consists of NGM282, NGM313, NGM120, NGM217, NGM621, NGM386 and NGM395 which are in clinical stage. NGM Biopharmaceuticals Inc. is based in San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $133.838B 8.91
Bio-Rad Laboratories (BIO.B) United States $23.483B 50.05
QIAGEN (QGEN) Netherlands $12.341B 20.90
Biohaven Pharmaceutical Holding (BHVN) United States $8.723B 0.00
Emergent Biosolutions (EBS) United States $2.813B 6.79
Arcus Biosciences (RCUS) United States $2.568B 0.00
Myovant Sciences (MYOV) United Kingdom $2.170B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.949B 0.00
Zymeworks (ZYME) Canada $1.323B 0.00
Ambrx Biopharma (AMAM) United States $0.509B 0.00
SQZ Biotechnologies (SQZ) United States $0.428B 0.00
Enzo Biochem (ENZ) United States $0.174B 51.29